
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CV Sciences Inc (QB) | USOTC:CVSI | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0035 | -10.61% | 0.0295 | 0.0295 | 0.034 | 0.03265 | 0.0295 | 0.031 | 238,667 | 20:00:10 |
[X] Form 10-K
|
[ ] Form 20-F
|
[ ] Form 11-K
|
[ ] Form 10-Q
|
[ ] Form 10-D
|
[ ] Form N-SAR
|
|
|
|
|
|
[ ] Transition Report on Form 10-K
|
|
|
|
[ ] Transition Report on Form 10-Q
|
|
|
|
For the Transition Period Ended: __________________________
|
|
(a)
|
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
[X]
|
(b)
|
The subject annual report, semi-annual report, or transition report or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form l0-Q or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
|
|
(c)
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
|
(1)
|
Name and telephone number of person to contact in regard to this notification
|
Joseph D. Dowling
|
|
619
|
|
876-4309
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding l2 months (or for such shorter period that the registrant was required to file such reports) been filed? If answer is no, identify report(s).
|
|
[X] Yes
|
[ ] No
|
|
|
|
|
|
|
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
|
[ ] Yes
|
[X] No
|
|
|
|
|
|
|
|
|
If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
|
|
|
|
Date: March 16, 2020
|
CV Sciences, Inc.
|
|
|
|
|
|
By:
|
/s/ Joseph D. Dowling
|
|
|
Joseph D. Dowling
|
|
|
Chief Executive Officer
|
|
|
|
1 Year CV Sciences (QB) Chart |
1 Month CV Sciences (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions